Abstract:OBJECTIVE To investigate the effect of mutant-type [(12)Asp]K-ras4B gene on the expression of estrogen receptor (ER) alpha and beta and their transcriptional activity as a transcription factor in endometrial carcinoma HEC-1A cell line. METHODS (1) Effect of [(12)Asp]K-ras4B on the expression of ER alpha and beta were determined using Western blot assay. (2) Eukaryotic expression plasmid pGL3-luciferase-ERE containing luciferase report gene and estrogen receptor element (ERE) was constructed, and co-transfected into NIH3T3 and HEC-1A cell lines with pEGFP-N1 to examine the effect of [(12)Asp]K-ras4B on ER transcription that is regulated by estradiol. In addition, they were transfected into pSV5-HER0 (containing full length wide type ERalpha cDNA) and pCMV-rafS621A (inhibiting raf kinase) plasmids to test the effect of [(12)Asp]K-ras4B/raf signal pathway on transcriptional activity of ER proteins. RESULTS (1) Protein level of ERs expressed in pcDI transfected control cells was low while it was increased for 3.6-fold (97 +/- 25, 349 +/- 67, P < 0.01) and 1.9-fold (128 +/- 37, 349 +/- 30, P < 0.05) in ERalpha and ERbeta, respectively, in pcDI-[(12)Asp]K-ras4B NIH3T3 cells after transfection. (2) In pcDI-[(12)Asp]K-ras4B NIH3T3 cells, the ratios for ERalpha and and ERbeta levels before transfection of rafS621A plasmids to that after the transfection, were 2.4:1 (724 +/- 45, 310 +/- 46, P < 0.05) and 1.8:1 (493 +/- 20, 284 +/- 20, P < 0.01), respectively; In HEC-1A cells, these ratios were 2.1:1 (566 +/- 22, 279 +/- 30, P < 0.01) and 2.4:1 (405 +/- 33, 165 +/- 15, P < 0.01), respectively. (3) In low serum (2%) culture condition, estradiol (E(2)) stimulated luciferase activity with an increase of 13-fold (130 +/- 42, 1681 +/- 242, P < 0.01) in pcDI-[(12)Asp] K-ras4B NIH3T3 cells, 19-fold (141 +/- 39, 2644 +/- 331, P < 0.001) in HEC-1A cells, respectively, when compared with those in the absence of E(2). (4) In pSV5-HER0 transfected pcDI-[(12)Asp] K-ras4B NIH3T3 cells and HEC-1A cells, compared to the untransfected cells, the ER transcriptional activity in the transfected cells increased markedly. The luciferase activity was increased for 8-fold (1048 +/- 91, 8099 +/- 452, P < 0.01) and 6-fold (2148 +/- 259, 12,705 +/- 2670, P < 0.001), respectively. rafS621A mutant had suppressive effects on luciferase activities in HEC-1A cells and pcDI-[(12)Asp]K-ras4B NIH3T3 cells. The ratio of luciferase activities in pcDI-[(12)Asp]K-ras4B NIH3T3 and HEC-1A cells, before and after transfection was 7.8:1 (1184 +/- 168, 152 +/- 27, P < 0.05) and 6.4:1 (1949 +/- 212, 304 +/- 60, P < 0.01), respectively. CONCLUSIONS (1) [(12)Asp]K-ras4B can enhance the expression of ERalpha and beta proteins. This may be correlated with [(12)Asp]K-ras4B/raf signaling pathway. (2) The effect of mutant-type [(12)Asp]K-ras4B gene on ERs transcriptional activity in HEC-1A cells appears to need E(2).

Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.

[Carcinogenesis and Its Mechanism of Mutant-Type[12asp]k-ras4b Gene].

[Regulation of [12Asp]k-Ras4b on Transcriptional Activity of Estrogen Receptor in Endometrial Carcinoma HEC-1A Cell Lines].

Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

RBPJ Inhibits the Movability of Endometrial Carcinoma Cells by Mir-155/Nf-κb/ros Pathway

Elevated Expression of P53 Gain-of-function Mutation R175H in Endometrial Cancer Cells Can Increase the Invasive Phenotypes by Activation of the EGFR/PI3K/AKT Pathway

Growth and Activation of PI-3K/PKB and Akt by Stromal Cell-Derived Factor 1α in Endometrial Carcinoma Cells with Expression of Suppressor Endoprotein PTEN

Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines

MEK inhibitors and DA‐Raf, a dominant‐negative antagonist of the Ras–ERK pathway, prevent the migration and invasion of KRAS‐mutant cancer cells

Oncogenic ERBB2 Aberrations and KRAS Mutations Cooperate to Promote Pancreatic Ductal Adenocarcinoma Progression.

A Novel Variant of ER-alpha, ER-alpha36 Mediates Testosterone-Stimulated ERK and Akt Activation in Endometrial Cancer Hec1A Cells.

K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3

TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation

TMPRSS2-ERG Promotes the Initiation of Prostate Cancer by Suppressing Oncogene-Induced Senescence

Recombinant Expression of Different Mutant K-ras Gene in Pancreatic Cancer Bxpc-3 Cells and Its Effects on Chemotherapy Sensitivity

Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/β-Catenin Signaling

Role of Suppressor Encoprotein PTEN in IGF-1 Induced Activation of ERK in Endometrial Carcinoma Cells

K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3K18ac through the MDM2-GCN5-SIRT7 axis

Sirtuin 2 in Endometrial Cancer: A Potential Regulator for Cell Proliferation, Apoptosis and RAS/ERK Pathway

KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility